WASHINGTON (dpa-AFX) - ViroPharma Inc. (VPHM) Monday announced the U.S. Food and Drug Administration has approved the supplement to the Cinryze Biologics License Application for industrial scale manufacturing changes.
The company expects completion of labeling for previously produced vials to take approximately six weeks before entering into the trade.
'We believe the approval of our supplement for industrial scale manufacturing now enables us to ensure Cinryze is available to any patient who chooses prophylaxis against their attacks of hereditary angioedema,' stated Dan Soland, ViroPharma's chief operating officer.
Copyright RTT News/dpa-AFX
© 2012 AFX News
